Symetis TAVR Buy Not About Throwing Shade On Lotus, BSX Insists

Europe's No. 3 in the transcatheter aortic valve replacement market, Boston Scientific, has inked a $435m deal to acquire its smaller Swiss rival Symetis. The US company bats away skeptics wondering whether the transaction signals Boston Scientific's shaky faith in its own Lotus valve platform, which is currently subject of a major recall. One casualty of the acquisition will be early-stage mitral valve technology company Middle Peak Medical, which Symetis had only bought a month ago.

Boston Scientific Corp.'s Mar. 30 announcement that it was acquiring Symetis SA, a smaller European rival in the transcatheter aortic valve replacement market, was greeted with a good dose of skepticism. Some believe that the move is an indication of declining confidence by the US company in its own TAVR platform, Lotus, which was pulled off the shelves and out of ongoing clinical trials in February due to a reported defect.

Under the terms of agreement, Boston Scientific will pay $435m upfront, all-cash, for Symetis. The latter is considered a relative latecomer to the TAVR scene. Its Acurate TA device, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiology

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Digital Health And AI Tools Advance Cardiac Event Prediction, SCAI 2025 Data Show

 
• By 

Out-of-hospital cardiac arrest remains one of the most challenging and resource-intensive emergencies in cardiovascular care. At SCAI 2025, clinicians presented a novel algorithm that improved triage decisions and reduced unnecessary interventions.

Thousands Of Cardiac Digital Twins Reveal Novel Connections With Mental Health

 

King’s College London, Imperial College London and The Alan Turing Institute constructed cardiac digital twins at scale, creating over 3,400, in a new study using UK Biobank data published in Nature Cardiovascular Research on 16 May.

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

More from Device Area

Pathogen Sharing System Part Of Global Pandemic Agreement

 

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.